Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学gynecologic oncology

Charlie Gourley

查理·戈利

PhD, FRCP

🏢University of Edinburgh Cancer Research UK Centre(爱丁堡大学癌症研究英国中心)🌐UK

Professor of Medical Oncology; Director, Nicola Murray Centre for Ovarian Cancer Research医学肿瘤学教授;尼古拉·默里卵巢癌研究中心主任

50
h-index
2
Key Papers
3
Awards
3
Key Contributions

👥Biography 个人简介

Charlie Gourley, PhD, FRCP is a Professor of Medical Oncology at the University of Edinburgh and Director of the Nicola Murray Centre for Ovarian Cancer Research, a specialist unit dedicated entirely to ovarian cancer biology and treatment. He is a pioneering researcher in BRCA-related ovarian cancer biology, PARP inhibitor mechanisms of resistance, and the role of homologous recombination deficiency (HRD) in treatment response. Dr. Gourley has led numerous investigator-initiated trials and genomic studies that have advanced understanding of ovarian cancer heterogeneity and resistance evolution.

Share:

🧪Research Fields 研究领域

Ovarian Cancer卵巢癌
PARP InhibitorsPARP抑制剂
Homologous Recombination Deficiency同源重组缺陷
BRCA MutationsBRCA突变
Rucaparib卢卡帕利
Platinum Resistance铂类耐药

🎓Key Contributions 主要贡献

Mechanisms of PARP Inhibitor Resistance

Identified key mechanisms by which ovarian tumors acquire resistance to PARP inhibitors, including BRCA reversion mutations and restoration of homologous recombination, guiding development of next-generation therapeutic strategies.

HRD Functional Assays

Developed and validated functional assays for homologous recombination deficiency that go beyond static BRCA mutation testing, enabling more accurate patient stratification for PARP inhibitor therapy.

SCOTROC Trial Series

Led the Scottish Gynaecological Cancer Trials Group (SCOTROC) clinical trial program evaluating novel chemotherapy and targeted agent combinations in ovarian cancer.

Representative Works 代表性著作

[1]

Rucaparib in Relapsed, Platinum-Sensitive High-Grade Ovarian Carcinoma (ARIEL2): an International, Multicentre, Open-Label, Phase 2 Trial

The Lancet Oncology (2017)

Demonstrated rucaparib efficacy and established genomic loss of heterozygosity as a predictor of response in BRCA wild-type patients.

[2]

Acquired Resistance to PARP Inhibitors in Ovarian Cancer

Annals of Oncology (2022)

Comprehensive review and original data on mechanisms of PARP inhibitor resistance and strategies to overcome them.

🏆Awards & Recognition 奖项与荣誉

🏆Cancer Research UK Future Leaders in Cancer Research Prize 2017
🏆Scottish Government Chief Scientist Award 2020
🏆BGCS Young Investigator Award 2015

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 查理·戈利 的研究动态

Follow Charlie Gourley's research updates

留下邮箱,当我们发布与 Charlie Gourley(University of Edinburgh Cancer Research UK Centre)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment